Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK41959 in MTAP-deleted advanced solid tumors
NCT06968572Phase 1Recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HSK41959 in solid tumor (advanced stage) (3 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Dose-Limiting Toxicities at 24 days, Maximum Tolerated Dose at 24 days and 2 more. Started Apr 2025; status: recruiting.
02
Drugs
HSK41959
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06968572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06968572.